CX3CL1 and neoplasm: Moreover, lack of sufficient DAMPs (due to a non-immunogenic dose of MTX-treated cancer cells) and excessive influx of immune cells (30, 58, 59) (due to a high CX3CL1 dose) might diminish activation of infiltrating immune cells, leading to an immunosuppressive phenotype and thus loss of the anti-tumour effect in the presence of a high dose of CX3CL1.